Daxor Corporation (DXR) - 10-K Summary for Fiscal Year Ended December 31, 2010
Business Context and Reporting Period
This Annual Report covers the fiscal year ended December 31, 2010. Daxor Corporation is a medical device manufacturer focused on the BVA-100 Blood Volume Analyzer, an instrument used to measure human blood volume, and its subsidiary, Scientific Medical Systems, which provides cryobanking services for blood and semen. The company operates two primary business segments: Equipment Sales and Related Services, and Cryobanking and Related Services. A significant portion of the company's financial stability is derived from a separate, non-operating investment portfolio.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Operating Revenue | $1,579,257 | $1,688,826 |
| Loss from Operations | $(5,659,111) | $(5,109,188) |
| Net Income | $4,968,264 | $5,822,758 |
| Investment Income (Net) | $14,009,267 | $12,261,060 |
| Realized Gains on Investments | $13,509,318 | $10,911,200 |
| Dividend Income | $2,226,198 | $2,936,976 |
| Cash and Cash Equivalents | $57,741 | $277,088 |
| Total Assets | $91,195,415 | $75,186,990 |
| Total Liabilities | $44,200,371 | $27,561,653 |
| Stockholders' Equity | $46,995,044 | $47,625,337 |
Margins: The company reported a gross profit margin of approximately 53.9% on total operating revenue. However, the operating margin was negative (-358%) due to high R&D and SG&A expenses relative to operating revenue.
Material Changes vs. Prior Period
- Operating Revenue Decline: Total operating revenue decreased by 6.5% to $1.58 million. This was driven by a 10.4% decrease in Volumex kit sales (3,152 kits sold in 2010 vs. 3,565 in 2009) and a slight decrease in equipment sales volume.
- Operating Loss Expansion: The loss from operations widened by $550,000 to $5.66 million. This increase was primarily attributed to a $302,000 rise in professional fees related to an ongoing SEC administrative proceeding.
- Investment Performance: Net income remained positive ($4.97 million) solely due to investment activities. Realized gains on the sale of securities increased by 23.8% to $13.5 million, offsetting the operating loss. Dividend income decreased by 24.2% to $2.23 million.
- Liquidity: Cash and cash equivalents dropped significantly from $277,088 to $57,741. Net cash used in operating activities was $5.69 million, while investing activities provided $9.4 million primarily through the sale of securities.
Guidance, Outlook, Risks, and Contingencies
- SEC Administrative Proceeding: The SEC has instituted proceedings claiming Daxor is an unregistered investment company rather than an operating company. The company incurred $747,639 in legal expenses for this proceeding in Q1 2011. If found to be an investment company, Daxor may be required to register as a Regulated Investment Company (RIC), necessitating the distribution of 90% of taxable income to shareholders.
- Reimbursement Risks: A 2008 CMS policy change reduced reimbursement for diagnostic radiopharmaceuticals (Volumex kits) by approximately 33% by bundling the procedure and drug costs. This policy remains in effect and limits hospital incentives to perform the test.
- Customer Concentration: Four hospitals accounted for 60.8% of revenue from Blood Volume Kits in 2010. The loss of any single major customer could materially impact the business.
- Patent Expiration: The patent for the BVA-100 Blood Volume Analyzer expired in 2010. The company is developing a next-generation system with total body albumin measurement capabilities and expects to file for a new patent in 2011.
- Key Person Risk: The company is heavily dependent on Dr. Joseph Feldschuh (CEO/Chief Scientist) for both scientific direction and all investment portfolio decisions.
Investor Verification Checklist
- Investment vs. Operating Status: Verify the outcome of the SEC administrative proceeding regarding the company's classification as an investment company.
- Investment Portfolio Sustainability: Assess the reliance on investment gains ($13.5M) to fund operating losses ($5.7M) and the sustainability of this model if market conditions change.
- Customer Concentration: Monitor the stability of the four hospitals representing over 60% of kit revenue.
- Reimbursement Policy: Track any changes in CMS or private insurance reimbursement policies for blood volume analysis.
- Patent Pipeline: Confirm the timeline and success of the new patent application for the albumin-measuring device to protect future revenue streams.